Understand the source comparison
Structural Comparison: Examorelin vs Other Growth Hormone Secretagogues
Examorelin belongs to the GHRP (growth hormone-releasing peptide) family, which includes GHRP-2, GHRP-6, ipamorelin, and Hexarelin. While all GHRPs share a common mechanism—ghrelin receptor agonism—their amino acid sequences, receptor selectivity profiles, and
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Examorelin belongs to the GHRP (growth hormone-releasing peptide) family, which includes GHRP-2, GHRP-6, ipamorelin, and Hexarelin. While all GHRPs share a common mechanism—ghrelin receptor agonism—their amino acid sequences, receptor selectivity profiles, and secondary effects differ meaningfully. Understanding these differences is critical for selecting the appropriate tool compound for specific research questions.
- GHRP-6, the earliest synthetic GHRP developed in the 1980s, contains the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH2. It potently stimulates GH release but also elevates cortisol and prolactin in a dose-dependent manner, and significantly increases appetite through strong activation of orexigenic pathways. GHRP-2 (D-Ala-D-β-Nal-Ala-Trp-D-Phe-Lys-NH2) was developed as a more selective analog with reduced appetite stimulation, though it still elevates cortisol and prolactin at higher doses.
- Examorelin (hexarelin) incorporates a D-2-methyl-Trp residue at position 2, which increases receptor binding affinity and reduces off-target activation. This structural modification makes examorelin one of the most potent GH secretagogues on a per-microgram basis—studies show that 100 mcg of examorelin produces plasma GH elevations comparable to 200–250 mcg of GHRP-2. However, examorelin does exhibit mild desensitization with chronic administration; repeated daily dosing leads to attenuated GH responses after 2–4 weeks, likely due to receptor downregulation or internalization.
- Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH2) was developed specifically to eliminate cortisol and prolactin elevation entirely. It's the most selective GHRP for GH release without secondary hormone effects, and it does not desensitize with chronic use in rodent models. Ipamorelin is structurally distinct in that it contains an aminoisobutyric acid (Aib) residue at position 1, which enhances resistance to enzymatic degradation. For cardiovascular research, examorelin remains preferred due to its direct cardioprotective receptor activity; for GH pulse modeling without desensitization, ipamorelin is typically the tool of choice.
- MK-677 (ibutamoren) is a non-peptide GHS-R1a agonist—a small molecule rather than a peptide. It has a much longer half-life (4–6 hours) and is orally bioavailable, making it useful for chronic dosing studies. However, MK-677 does increase appetite significantly and elevates cortisol in a subset of subjects, particularly at doses above 25 mg daily. Structurally, examorelin and MK 677 are not directly comparable—one is a hexapeptide requiring reconstitution and injection, the other a synthetic small molecule suitable for oral or subcutaneous delivery.
- For researchers sourcing peptides, the distinction between these analogs isn't academic—it determines experimental design. Studies investigating acute GH release dynamics benefit from examorelin's high receptor affinity and short half-life. Chronic administration protocols examining long-term GH exposure without desensitization require ipamorelin or MK-677. Cardiovascular protection studies use examorelin specifically for its cardioprotective receptor signaling independent of GH.
- Real Peptides supplies examorelin, Hexarelin, Ipamorelin, and GHRP-2 as research-grade lyophilized powders synthesized under USP standards—each batch includes third-party purity verification via HPLC and mass spectrometry to confirm amino acid sequence accuracy and absence of truncated analogs or contaminants.